ArticleFrontiers in public health2023

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.

Xueyan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.